BATTALION

Single-arm multicenter Phase II trial to investigate the efficacy of Botensilimab and Balstilimab in combination with gemcitabine/cisplatin for previously untreated patients with advanced or metastatic biliary tract cancer

(CORAL-1, AIO HB XXXX) (BAlstilimab boTensilimab in the TreAtment of choLangIOcellular carcinoma)

II

interventionell

National

Status: In Vorbereitung

Zeitraum

2024

2026

Zentren

15

Zentren gesucht

Patienten

40

20.09.2023

Klinische Settings

IV

1st line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Förderer

Agenus Inc.

Identifier

AIO-HEP-0123

Kontakt

Leitung

Prof. Dr. med. Dominik Paul Modest

Ansprechpartner*in

Prof. Dr. med. Dominik Paul Modest
E-Mail dominik.modest@charite.de